Comprehensive analysis of DNA damage repair deficiency in 10,284 pan–cancer study
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background: Disruption of the DNA damage repair (DDR) gene is related to cancer progression, treatment selection, and is subjected to radiation and targeted therapies with limited success. This paper conducted a comprehensive analysis to explore the distribution of DDR mutations in Chinese pan-cancer patients. Methods: A total of 10,284 consecutive cases were analyzed in 24 cancer types [non-small cell lung cancer (NSCLC) 29.0%, liver 12.0%, colorectum 10.7%, etc.]. Tumor tissue samples were subjected to next generation sequencing (NGS) using a 381 gene panel incorporating 100 microsatellite loci. The association of deleterious somatic DDR mutation (del-sDDRmut) with tumor mutational burden (TMB), microsatellite instability (MSI), programmed cell death-ligand 1 (PD-L1) expression of pan-cancers was evaluated. Genomic and clinical data from public cohorts of immunotherapy were analyzed to demonstrate the association between del-sDDRmut and clinical survival. Results: Del-sDDRmut were found in 802 (7.6%) of all cases, and were most common in cancers of the endometrium, prostate, bladder, etc. cancer with a higher TMB also had a higher prevalence of mutations in DDR pathways. The results of the ridge regression analysis showed that 20 DDR genes were significantly associated with TMB [false discovery rate (FDR) <0.01]. A total of 8,899 patients had both TMB and MSI-data in pan-cancers. Seventy-four percent of patients with MSI-high (MSI-H) were accompanied by del-sDDRmut/TMB-high (TMB-H). The largest proportion of patients with microsatellite stability (MSS) with DDR mutations were classified as TMB-H. The top 6 tumors (NSCLC, melanoma, esophagus, head and neck, thyroid, and mediastinal) had the highest prevalence of PD-L1 ≥1%, and DDR mutations were significantly associated with a higher percent of PD-L1 positive (P<0.05). Furthermore, in the immune cohort analysis of NSCLC, patients with del-sDDRmut significantly improved median progression-free survival (mPFS) and median overall survival (mOS) compared to wild-type DDR patients (P=0.002 and P=0.043), with higher TMB observed (P<0.001). Conclusions: This study explored the association of DDR mutations with TMB, MSI-H, and PD-L1 expression, and revealed that patients with DDR mutations have a significantly improve prognosis than wild-type patients on immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cutaneous melanoma tumors contain somatic mutations in the genes that are associated with the DNA damage response, particularly in repair genes, in addition to an abundance of C > T transitions [ 45 , 46 ].”
From Differential Induction of Reactive Oxygen Species and Expression of Antioxidant Enzymes in Human Melanocytes Correlate with Melanin Content: Implications on the Response to Solar UV and Melanoma Susceptibility (2022) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594 · cited 1×
“Pathogenic and possible pathogenic mutations were explained by bioinformatics experts according to the consensus of previous reports and the recommendations of the American College of Medical Genetics and Genomics and the Association of Molecular Pathology (18).”
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522 · cited 1×
“The coefficients were determined by the method developed by Cule and De Iorio (19 ).”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 1×
“Deficient MMR (dMMR)/MSI-high (MSI-H), mainly caused by mutations in the MMR pathway genes, has been approved by the FDA to guide ICIs in pan-cancer (14,15).”
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071 · cited 2×
“Five independent cohorts (Rizvi 2015, Rizvi 2018, Miao 2018, Samstein 2019, and Hellmann 2018; study cohort) (20-24) with data from patients with advanced NSCLC were used to analyze the correlation of del-sDDR and immunotherapy.”
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · cited 1×
“Furthermore, germline mutations in DDR genes cause sensitivity to PARP inhibitors in advanced solid tumors, including ovarian, pancreatic, and breast cancer (34,35).”
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Mok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,303 · cited 1×
“Apart from MSI status and TMB, PD-L1 expression by IHC has been related to responses to ICI, and the pembrolizumab monotherapy has been approved for patients with PD-L1 expression ≥1% (29).”
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185 · cited 2×
“…to castration resistance in patients with de novo metastatic and castration sensitive PCa (mCSPC), who may earlier benefit from the treatment of poly (ADP-ribose) polymerase (PARP) inhibitors or platinum-based chemotherapy if the status of gDDRm was identified at the diagnosis (9,32,33).”
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671 · cited 1×
“Furthermore, germline mutations in DDR genes cause sensitivity to PARP inhibitors in advanced solid tumors, including ovarian, pancreatic, and breast cancer (34,35).”
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649 · cited 5×
“NHEJ had relatively lower mutation frequencies, mainly in the liver, lung, pancreas, sarcoma, kidney, etc. ( Figure 2B ).”
InfluentialEndogenous DNA damage as a source of genomic instability in cancer
Tubbs, A., & Nussenzweig, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.002 · Cited by 1,452 · cited 1×
“DDR genes play a crucial role in maintaining genome stability (36).”
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367 · cited 2×
“Five independent cohorts (Rizvi 2015, Rizvi 2018, Miao 2018, Samstein 2019, and Hellmann 2018; study cohort) (20-24) with data from patients with advanced NSCLC were used to analyze the correlation of del-sDDR and immunotherapy.”
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196 · cited 1×
“Several agents, such as PARP inhibitors, immune checkpoint inhibitors (ICIs), have recently received FDA approval in multiple types of solid tumors (2-5).”
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Knijnenburg, T. A., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., Fan, H., Shen, H., Way, G. P., Greene, C. S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.076 · Cited by 1,136 · cited 1×
“Around 200 genes have been identified as directly involved in DDR and the resulting DNA damage checkpoint ( 1 ).”
Self-citationHellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.018 · Cited by 1,095 · cited 2×
“Five independent cohorts (Rizvi 2015, Rizvi 2018, Miao 2018, Samstein 2019, and Hellmann 2018; study cohort) (20-24) with data from patients with advanced NSCLC were used to analyze the correlation of del-sDDR and immunotherapy.”
Castro, E., Goh, C., Olmos, D., Saunders, E., Leongamornlert, D., Tymrakiewicz, M., Mahmud, N., Dadaev, T., Govindasami, K., Guy, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1882 · Cited by 850 · cited 1×
“Similarly, gDDRm, especially BRCA1/2 and ATM alterations, have been reported to be associated with aggressive disease and poor survival of PCa (25,31).”
Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01035 · Cited by 694 · cited 1×
“…niraparib, and talazoparib) have been approved by FDA in at least one type of cancer with somatic or germline BRCA mutations or gene mutations in the HRR pathway, including ovarian cancer, breast cancer ( 7), metastatic castration-resistant prostate cancer (PCa) (8), pancreatic cancer (4), etc.”
Zhao, P., Li, L., Jiang, X., & Li, Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0738-1 · Cited by 682 · cited 1×
“dMMR/MSI-H is the first FDA-approved pan-cancer biomarker (39).”
DNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645 · cited 1×
“Several agents, such as PARP inhibitors, immune checkpoint inhibitors (ICIs), have recently received FDA approval in multiple types of solid tumors (2-5).”
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Miao, D., Margolis, C. A., Vokes, N. I., Liu, D., Taylor-Weiner, A., Wankowicz, S. M., Adeegbe, D., Keliher, D., Schilling, B., Tracy, A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0200-2 · Cited by 620 · cited 3×
“Five independent cohorts (Rizvi 2015, Rizvi 2018, Miao 2018, Samstein 2019, and Hellmann 2018; study cohort) (20-24) with data from patients with advanced NSCLC were used to analyze the correlation of del-sDDR and immunotherapy.”
The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy
Goldstein, M., & Kastan, M. B. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-081313-121208 · Cited by 590 · cited 1×
“For chemotherapy, if tumor cells have DDR mutations, genotoxic drugs, including platinum, are susceptible to cause DNA damage that exceeds the repair capacity of DDR systems, which will stop cell replication and induce cell apoptosis or death (11).”
Teo, M. Y., Seier, K., Ostrovnaya, I., Regazzi, A. M., Kania, B. E., Moran, M. M., Cipolla, C. K., Bluth, M. J., Chaim, J., Al-Ahmadie, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7740 · Cited by 544
Disis, M. L., Taylor, M. H., Kelly, K., Beck, J. T., Gordon, M., Moore, K. M., Patel, M. R., Chaves, J., Park, H., Mita, A. C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6258 · Cited by 437 · cited 1×
“However, a phase 1b study showed that BRCA status was not associated with the efficacy of anti-PD-L1 therapy in patients with recurrent or refractory ovarian cancer (42).”
Na, R., Zheng, S. L., Han, M., Yu, H., Jiang, D., Shah, S., Ewing, C. M., Zhang, L., Novakovic, K., Petkewicz, J., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.11.033 · Cited by 343 · cited 5×
“ATM and MSH6 were the top 2 DDR gene somatic alterations in a patient with PCa, while in germline alterations, BRCA2 , BARD1 , and ATM were the top 3 DDR genes.”
InfluentialSelf-citationTeo, M. Y., Bambury, R. M., Zabor, E. C., Jordan, E., Al-Ahmadie, H., Boyd, M. E., Bouvier, N., Mullane, S. A., Cha, E. K., Roper, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2520 · Cited by 280 · cited 1×
“A recent study has shown that at least one gene alteration among 34 DDR genes was associated with improved clinical outcomes in platinum-treated patients with advanced urothelial carcinoma (12).”
Pomerantz, M. M., Spisák, S., Jia, L., Cronin, A. M., Csabai, I., Ledet, E., Sartor, A. O., Rainville, I., O'Connor, E. P., Herbert, Z. T., et al. (2017) · Cancer · doi:10.1002/cncr.30808 · Cited by 257 · cited 1×
“…to castration resistance in patients with de novo metastatic and castration sensitive PCa (mCSPC), who may earlier benefit from the treatment of poly (ADP-ribose) polymerase (PARP) inhibitors or platinum-based chemotherapy if the status of gDDRm was identified at the diagnosis (9,32,33).”
Wang, Z., Zhao, J., Wang, G., Zhang, F., Zhang, Z., Zhang, F., Zhang, Y., Dong, H., Zhao, X., Duan, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1814 · Cited by 241 · cited 2×
“Co-mutation in the DDR gene (HRR-MMR or HRR-BER) was found to be a promising predictor of ICB response for future clinical application (13).”
Self-citationPerioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC)
Chen, K., Zhao, H., Shi, Y., Yang, F., Wang, L. T., Kang, G., Nie, Y., & Wang, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1213 · Cited by 239 · cited 1×
“POLE / POLD1 , in the BER pathway, are potential biomarkers of genomic instability and response to immunotherapy among different types of cancer (40).”
Norquist, B. M., Brady, M. F., Harrell, M. I., Walsh, T., Lee, M. K., Gulsuner, S., Bernards, S. S., Casadei, S., Burger, R. A., Tewari, K. S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1327 · Cited by 230 · cited 1×
“These are limited to patients with breast cancer gene ( BRCA ) mutations, and patients with other DDR mutations, including ATM, ATR, non-BRCA HRR mutations ( RAD51C , RAD51D , PALB2 , etc.) were found to have a response to PARP inhibitors (9,10).”
Gourley, C., Balmaña, J., Ledermann, J. A., Serra, V., Dent, R., Loibl, S., Pujade-Lauraine, E., & Boulton, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02050 · Cited by 194 · cited 1×
“…), checkpoint kinase ( CHEK1 / CHEK2 ), ataxia telangiectasia mutated ( ATM ), or ataxia telangiectasia and Rad3-related ( ATR ) inhibitors involved in the calcineurin like EF-hand protein ( CHP ) pathway and polyadenosine diphosphate-ribose polymerase ( PAPR1/2 ) inhibitors in the BER pathway (6).”
Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway
Yazinski, S. A., & Zou, L. (2016) · Annual Review of Genetics · doi:10.1146/annurev-genet-121415-121658 · Cited by 175 · cited 2×
“to stress phosphorylates transducers, including CHK (27).”
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies
Minchom, A. R., Aversa, C., & Lopez, J. S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786658 · Cited by 152 · cited 1×
“We can assume that the ATR mutant/TP53 mutant with elevated TMB may be the best candidate gene for the combination of ATR inhibitor and immunotherapy (28).”
Su, D., Zhang, D., Chen, K., Lu, J., Wu, J., Cao, X., Ying, L., Jin, Q., Ye, Y., Xie, Z., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0591-4 · Cited by 102 · cited 1×
“The filtered variables were then filtered according to their unique base quality and supporting read depth (16).”
Hashimoto, T., Kurokawa, Y., Takahashi, T., Miyazaki, Y., Tanaka, K., Makino, T., Yamasaki, M., Nakajima, K., Ikeda, J.-I., Mori, M., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-018-00918-4 · Cited by 72 · cited 1×
“Early reports have noted that dysfunctional MLH1 was associated with chemoresistance and did not prolong survival after neoadjuvant chemotherapy in gastric cancer (26), but has not been reported in cervical cancer.”
Yu, W., Wu, J., Gu, W., Wang, J., Lin, G., Qin, X., Dai, B., Gan, H., Ye, D., & Zhu, Y. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0495 · Cited by 29 · cited 1×
“Furthermore, it has shown an increased risk of progression to castration resistance in patients with de novo metastatic and castration sensitive PCa (mCSPC), who may earlier benefit from the treatment of poly (ADP-ribose) polymerase (PARP) inhibitors or platinum-based chemotherapy if the status of gDDRm was identified…”
Na, R., Wu, Y., Jiang, G., Yu, H., Lin, X., Wang, M., Conran, C., Fantus, R. J., Zhang, N., Liu, S., et al. (2018) · British Journal of Urology · doi:10.1111/bju.14370 · Cited by 20 · cited 1×
“In a study investigating the germline mutation status of DDR genes (gDDRm) in 98 patients with bladder cancer (BCa) by Na et al. (30), germline mutations in DDR genes were associated with BCa risk and poor prognosis.”
Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
Mukherjee, S., & Asaithamby, A. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.03.07 · Cited by 3 · cited 1×
“…niraparib, and talazoparib) have been approved by FDA in at least one type of cancer with somatic or germline BRCA mutations or gene mutations in the HRR pathway, including ovarian cancer, breast cancer ( 7), metastatic castration-resistant prostate cancer (PCa) (8), pancreatic cancer (4), etc.”
Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors.
Dumbrava, E. E. I., Brusco, L., Daniels, M. S., Wathoo, C., Shaw, K. R. M., Lu, K. H., Zheng, X., Strong, L. C., Litton, J. K., Arun, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.11567 · Cited by 1 · cited 1×
“In this study, we observed a trend of greater TMB in tumors harboring DDR somatic mutations than germline mutations in pan-cancer, which was consistent with a previous study (37).”
Cited by
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85
“For example, PARPi promotes CAR-T infiltration in the TME via the cGAS-STING pathway.”
BackgroundInfluentialOpportunities and challenges of targeting cGAS–STING in cancer
Lu, C., Wang, W., & Fu, Y. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00894-9 · Cited by 79
Upadhyay, P. R., Starner, R. J., Swope, V. B., Wakamatsu, K., Ito, S., & Abdel-Malek, Z. A. (2022) · Antioxidants · doi:10.3390/antiox11061204 · Cited by 30
“Cutaneous melanoma tumors contain somatic mutations in the genes that are associated with the DNA damage response, particularly in repair genes, in addition to an abundance of C > T transitions [45,46].”
BackgroundFu, H., Fu, Z., Mao, M., Si, L., Bai, J., Wang, Q., & Guo, R. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104084 · Cited by 33
Yu, X., Zhu, L., Wang, T., Li, L., Liu, J., Che, G., & Zhou, Q. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188910 · Cited by 16
Metadata
- Authors
- Xiao, Y., Lu, D., Lei, M., Xie, W., Chen, Y., Zheng, Y., Wang, C., Zhao, J., Zhu, Z., Zhao, X., Huang, M., Lin, Y., Li, Z., & Yang, L.
- Affiliations
- Army Medical University (CN)
- Nanfang Hospital (CN)
- Chongqing University (CN)
- 3D Medicines, Inc. (China) (CN)
- Traditional Chinese Medicine Hospital of Kunshan (CN)
- Jieyang People's Hospital (CN)
- Corresponding author
- Lin, Youen
- Li, Zhongjun
- ORCID
- Venue
- Annals of Translational Medicine
- Publisher
- AME Publishing Company
- Published
- 2021-11
- Volume
- 9
- Issue
- 22
- Pages
- 1661-1661
- ISSN
- 2305-5839 (ISSN-L)
- 2305-5847
- PMC
- PMC8667116
- OpenAlex
- W3217378264
- Cited by
- 22
- References
- 45
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 4
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Annals of Translational Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- DNA repair, somatic mutations, tumor mutational burden, microsatellite instability, PD-L1 expression, pan-cancer, non-small cell lung cancer, immunotherapy response, progression-free survival, overall survival, Chinese patients, endometrial cancer, prostate cancer, bladder cancer, melanoma, esophageal cancer, head and neck cancer, thyroid cancer, mediastinal cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.